One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story
Werewolf Therapeutics surged after announcing a $500 million merger with Ambros Therapeutics, putting focus on Israel Englander's holding.
A biotech company that an investor named Israel Englander owns just agreed to merge with another company for $500 million. When smart investors pick a company and something good happens to it, that's a signal that their choices might be working out.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.